- Home
- GH
as 06-20-2025 4:00pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.9B | IPO Year: | 2018 |
| Target Price: | $54.35 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.14 - $52.92 | Next Earning Date: | 08-06-2025 |
| Revenue: | $773,996,000 | Revenue Growth: | 28.20% |
| Revenue Growth (this year): | 23.14% | Revenue Growth (next year): | 21.42% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| POTTER MYRTLE S | GH | Director | Jun 12 '25 | Sell | $49.70 | 2,626 | $130,512.20 | 18,180 | |
| Joyce Meghan V. | GH | Director | Jun 12 '25 | Sell | $47.22 | 3,337 | $157,573.14 | 11,150 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | Jun 5 '25 | Sell | $50.06 | 119,284 | $5,974,363.95 | 2,069,456 | |
| Kalia Kumud | GH | Chief Information Officer | Jun 3 '25 | Sell | $46.39 | 4,000 | $185,561.60 | 18,765 | |
| Joyce Meghan V. | GH | Director | Jun 2 '25 | Sell | $41.66 | 100 | $4,166.00 | 11,150 | |
| Tariq Musa | GH | Director | May 19 '25 | Sell | $40.04 | 116 | $4,644.64 | 3,479 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | May 1 '25 | Sell | $50.20 | 120,716 | $5,936,572.01 | 2,069,456 | |
| Tariq Musa | GH | Director | Apr 17 '25 | Sell | $44.79 | 116 | $5,195.64 | 3,479 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Zacks
13 hours ago
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Investor's Business Daily
13 hours ago
Dow Jones Futures Rise As Trump Buys Time For Iran; Tesla Robotaxi To Have Safety Monitor
StockStory
8 days ago
3 of Wall Street’s Favorite Stocks Facing Headwinds
StockStory
10 days ago
2 Mooning Stocks Worth Your Attention and 1 to Be Wary Of
Business Wire
11 days ago
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
MT Newswires
11 days ago
Guardant Health Insider Sold Shares Worth $5,974,364, According to a Recent SEC Filing
Business Wire
12 days ago
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
Zacks
15 days ago
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.